SARS CORONAVIRUS 2 RECOMBINANT VECTORS EXPRESSING REPORTER GENES, DERIVED FROM GH CLADE SARS CORONAVIRUS 2 OF KOREAN ISOLATE, AND THE PRODUCTION METHOD THEREFOR

NUCLEIC ACID VACCINES ENCAPSULATED WITH NANOALUMINOSILICATE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV)

METHOD FOR MANUFACTURING INACTIVATED SARS-COV-2 VACCINE, INACTIVATED SARS-COV-2 VACCINE, METHOD FOR PURIFYING SARS-COV-2 OR INACTIVATED SARS-COV-2, AND SARS-COV-2 ANTIGEN COMPOSITION OR INACTIVATED SARS-COV-2 ANTIGEN COMPOSITION

LIVE-ATTENUATED SARS-COV-2 VACCINE

MODIFIED CORONAVIRUS S PROTEIN

ANCESTRAL PROTEIN SEQUENCES AND PRODUCTION THEREOF

VIRUS-LIKE PARTICLE STABLY EXPRESSED BY ANIMAL CELLS AS VACCINE ANTIGEN AGAINST COVID-19 AND INFLUENZA VIRUS

BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION

VACCINE CONSTRUCT AND USES THEREOF

BETA-CORONAVIRUS FUSION RECOMBINANT PROTEIN, AND PREPARATION METHOD AND APPLICATION THEREOF

SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF

EXPRESSION OF MULTIPLE IMMUNE-ACTIVE MOLECULES IN GENETICALLY-MODIFIED FILAMENTOUS FUNGI

EXPRESSION OF THE SPIKE S GLYCOPROTEIN OF SARS-COV-2 FROM AVIAN PARAMYXOVIRUS TYPE 3 (APMV3)

CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES

METHODS AND COMPOSITIONS FOR BAT IPSC PREPARATION AND USE

FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES

Novel Adjuvant Compositions

Vaccine Antigen

PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME

METHODS AND COMPOSITIONS FOR PURIFICATION OF TRIMERIC FUSION PROTEINS

MODIFIED CORONAVIRUS STRUCTURAL PROTEIN

RESPIRATORY VIRUS COMBINATION VACCINES

Methods for Providing a Vaccine

OPTIMAL PRODUCTION OF SARS-COV-2 VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN MAMMALIAN CELLS

A TRANS-COMPLEMENTATION SYSTEM FOR SARS-COV-2

PARTICLES, DNA & RNA

FUSION PROTEINS COMPRISING SARS-COV-2 NUCLEOCAPSID DOMAINS

METHOD FOR IN VITRO PROLIFERATING VIRUS BELONGING TO FAMILY CORONAVIRIDAE, METHOD FOR PRODUCING NEUTRALIZING ANTIBODY TO VIRUS BELONGING TO FAMILY CORONAVIRIDAE, AND METHOD FOR PRODUCING INFECTION MODEL OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS

BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)

COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES

Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof

SARS-COV-2 RECOMBINANT N PROTEIN, AND PREPARATION METHOD AND PURIFICATION METHOD THEREFOR

VIRUS-LIKE PARTICLES

Adjuvant compositions

Coronaviruses epitope-based vaccines

VIRUS LIKE PARTICLE PRODUCTION IN PLANTS

CORONAVIRUSES EPITOPE-BASED VACCINES

CORONAVIRUS PROTEINS AND ANTIGENS

Highly efficient influenza matrix (M1) proteins

Attenuated infectious bronchitis virus

Adjuvant compositions

Coronaviruses epitope-based vaccines

COMPOSITION COMPRISING PEDV ANTIGENS AND METHODS FOR MAKING AND USING THE COMPOSITION

Adjuvant compositions

Highly efficient influenza matrix (M1) proteins

Coronavirus

Coronavirus proteins and antigens

Purification method for embryo—derived infectious bronchitis virus (IBV)

Highly efficient influenza matrix (M1) proteins

Adjuvant compositions

Highly efficient influenza matrix (M1) proteins

Production of vaccines

Adjuvant compositions

Cell line for producing coronaviruses

Systems for detection and production of respiratory, herpes and enteric viruses

Severe acute respiratory syndrome coronavirus

Production of vaccines

Production of vaccines